CD274 and non-small cell lung carcinoma: In advanced-stage NSCLC patients, the response rates to these ICIs partly correlate with the level of PD-L1 expression, and patients with a high PD-L1 tumour proportion score (TPS) have shown greater response to ICIs versus patients who have a low TPS.